---

Efficacy of different doses of mifepristone in the management of uterine leiomyoma in a tertiary care centre

---

Original Article

Author Details : Sangeetha Marimuthu, Ushadevi Gopalan*

Volume : 10, Issue : 3, Year : 2023

Article Page : 272-277

https://doi.org/10.18231/j.ijogr.2023.056

Suggest article by email

Get Permission

---

Abstract

Background: Leiomyoma or uterine fibroid are benign tumours that arise from the smooth muscles of the uterus. The leiomyomas are common gynaecological problem encountered among reproductive age group women. Mifepristone is the commonly used drug in the management of uterine leiomyoma. The objective of the study were to study the efficacy and safety of 10mg and 25mg of Mifepristone in the management of uterine fibroid.
Materials and Methods: This is a randomized controlled Trial conducted in tertiary care centre. Hundred women with the diagnosis of uterine fibroid were taken up for the study. Group-A (n=50) were given Mifepristone 10mg and Group-B (n=50) were given Mifepristone 25mg daily for a period of 3 months. Reduction in the size of fibroid were assessed at the end of 3 months.
Results: At the end of 3months there was a significant reduction in both menstrual blood loss and fibroid volume in both the groups (p<0> Conclusion: Both Mifepristone 10mg and 25mg had similar clinical outcomes but 10mg had better compliance and lower side effects. Hence, 10mg can be preferred over 25mg in order to bring about effective management of uterine fibroid.
 

Keywords: Leiomyoma, Menorrhagia, Fibroid volume, Mifepristone.

How to cite : Marimuthu S, Gopalan U, Efficacy of different doses of mifepristone in the management of uterine leiomyoma in a tertiary care centre. Indian J Obstet Gynecol Res 2023;10(3):272-277

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.